Completed PHASE2 INTERVENTIONAL 3-arm NCT00243932

Clinical Trial of High Dose CoQ10 in ALS

Sponsor: Columbia University

Conditions Amyotrophic Lateral Sclerosis Lou Gehrig's Disease

Updated 8 times since 2017 Last updated: Apr 15, 2024 Started: Apr 30, 2005 Primary completion: Mar 31, 2008 Completion: Mar 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00243932, this PHASE2 trial focuses on Amyotrophic Lateral Sclerosis and Lou Gehrig's Disease and remains completed. Sponsored by Columbia University, it has been updated 8 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2024 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Jun 2024 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Columbia University
National Institute of Neurological Disorders and Stroke (NINDS)

Data source: Columbia University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States , Burlington, United States , Chicago, United States , Cleveland, United States , Denver, United States , Kansas City, United States , Lexington, United States , Little Rock, United States , Minneapolis, United States , New Haven, United States and 7 more locations